On December 9, 2024 Cimeio Therapeutics reported that it has entered a research collaboration with Kyowa Kirin Co., Ltd. (Kyowa Kirin) to develop a novel therapy for diseases with high unmet need (Press release, Cimeio Therapeutics, DEC 10, 2024, View Source [SID1234648894]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The partnership combines Cimeio’s proprietary Shielded Cell and Immunotherapy (SCIP) platform with Kyowa Kirin’s expertise in cellular therapies and underscores both companies’ commitment to using emerging cell and gene therapy technologies to develop new ways to treat patients. Under the terms of the agreement, Cimeio is eligible to receive an upfront payment and two years of research funding. Upon Kyowa Kirin’s exercise of a commercial license option, Cimeio will be eligible for development and commercial milestones as well as royalties on sales of potential products arising from the partnership. Further terms are not disclosed.
Cimeio’s SCIP platform is based on the development of novel immunotherapies enabled by epitope-shielded cells. These cells contain modified variants of naturally occurring cell surface proteins that maintain their function but are resistant to depletion by the paired immunotherapy. These shielded cells enable the development of powerful therapeutics for previously undruggable targets, targeted conditioning for HSC transplant, and immune system reset amongst other applications.
"We are thrilled to collaborate with Kyowa Kirin, a company with a rich history of investing in innovative technologies that have the potential to significantly improve outcomes for patients with serious conditions," said Dr. Stefanie Urlinger CSO of Cimeio. "This partnership represents a significant step forward for our company and mission."
"Kyowa Kirin and Cimeio share the vision for the potential of therapeutics enabled by epitope-shielded cells," said Yoshifumi Torii, Ph.D, Executive Officer, Senior Vice President, Head of Research Division of Kyowa Kirin. "With this partnership we believe we can develop a safe and effective therapy for diseases that in the past have been incredibly difficult to treat, and we’re looking forward to working with the talented team at Cimeio."